Realising the urgency for the industry to take a pro-active stance to create patient awareness and education about clinical research, The Association of Biotechnology Led Enterprises (ABLE) is planning to set up a clinical trials committee.

This move is to assist the government and the industry to share information arising from drug trials in public domain in an accessible and anonymous form. However, this must be balanced with the need to ensure disclosure policies protect patients’ personal data, companies’ intellectual property rights and confidential commercial information in order to continue to develop innovative medicines in areas of unmet clinical need.